Medera's Novoheart partners with AstraZeneca on First Bioengineered Human Models of Heart Failure
Fox 40,
• Heart failure is a global pandemic affecting at least 64 million people worldwide and costing over US$100B per year • Heart…
Medera’s Novoheart partners with AstraZeneca on First Bioengineered Human Models of Heart Failure
Businessfortnight,
BOSTON, MASSACHUSETTS, UNITED STATES, October 27, 2022 /EINPresswire.com/ — • Heart failure is a world pandemic affecting no…
Medera’s Novoheart partners with AstraZeneca on First Bioengineered Human Models of Heart Failure
EINPresswire,
BOSTON, MASSACHUSETTS, UNITED STATES, October 27, 2022 / • Heart failure is a global pandemic affecting at least 64 million…
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca
Drug Discovery Today,
VANCOUVER, British Columbia, Nov. 26, 2019 -- Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem…
Heart-in-a-Jar Collaboration Could Accelerate Drug Discovery for Heart Failure
Biospace,
Heart failure is a chronic disease that impacts millions of people around the globe and has an estimated economic burden of…
Novoheart collaborates with AstraZeneca to develop world’s first human heart-in-a-jar model of heart failure
The Medical News,
Novoheart (“Novoheart” or the “Company”), a global stem cell biotechnology company, is pleased to announce a collaboration with…